Presentation is loading. Please wait.

Presentation is loading. Please wait.

Potential beneficial cellular pleotropic effects of DPP-4 inhibitors.

Published byBedřich Havel Modified over 5 years ago

Similar presentations

Presentation on theme: "Potential beneficial cellular pleotropic effects of DPP-4 inhibitors."— Presentation transcript:

1 Potential beneficial cellular pleotropic effects of DPP-4 inhibitors.
Potential beneficial cellular pleotropic effects of DPP-4 inhibitors. Antithrombotic, anti-inflammatory, and atheroprotective effects are key players in the CV arena. *Makdissi A, Ghanim H, Vora M, Green K, Abuaysheh S, Chaudhuri A, Dhindsa S, Dandona P: Sitagliptin exerts an antinflammatory action. J Clin Endocrinol Metab 97:3333–3341, 2012. Vani P. Sanon et al. Clin Diabetes 2014;32: ©2014 by American Diabetes Association

Download ppt "Potential beneficial cellular pleotropic effects of DPP-4 inhibitors."

Similar presentations

GLP-1 Effectiveness, Mechanisms of Action and Potential Part 2.

GLP-1 Effectiveness, Mechanisms of Action and Potential Part 2.
Vascular Effects of Insulin: Implications for Hyperglycemia Management.

Vascular Effects of Insulin: Implications for Hyperglycemia Management.
Β-Cell (Islet Cell) Classification Model- Implications for Therapy: Targets for Therapies/ New Guidelines Medication Choice Based on 1.Glycemic Efficacy.

Β-Cell (Islet Cell) Classification Model- Implications for Therapy: Targets for Therapies/ New Guidelines Medication Choice Based on 1.Glycemic Efficacy.
Fig. 1. The cumulative incidence of diabetic complication in middle-age-onset and elderly-onset diabetes. (A) Cumulative incidence (%) of coronary revascularization.

Fig. 1. The cumulative incidence of diabetic complication in middle-age-onset and elderly-onset diabetes. (A) Cumulative incidence (%) of coronary revascularization.
Fig. 1. Intravenous glucose infusion rates during an isoglycemic intravenous glucose infusion (IIGI) study in subjects with (A) normal glucose tolerance.

Fig. 1. Intravenous glucose infusion rates during an isoglycemic intravenous glucose infusion (IIGI) study in subjects with (A) normal glucose tolerance.
Nat Clin Pract Endocrinol Metab 3: 279–289 doi: /ncpendmet0447

Nat Clin Pract Endocrinol Metab 3: 279–289 doi: /ncpendmet0447
Nat. Rev. Endocrinol. doi: /nrendo

Nat. Rev. Endocrinol. doi: /nrendo
Copyright © 2017 American Academy of Pediatrics.

Copyright © 2017 American Academy of Pediatrics.
Fig. 1. Effect of bariatric surgery on BMI and plasma leptin concentration. BMI (A) and plasma leptin concentrations (B) were determined in 27 morbidly.

Fig. 1. Effect of bariatric surgery on BMI and plasma leptin concentration. BMI (A) and plasma leptin concentrations (B) were determined in 27 morbidly.
Plasma insulin concentrations (A) and insulin secretion rates (B) in response to molar increments of plasma glucose concentration during the graded glucose.

Plasma insulin concentrations (A) and insulin secretion rates (B) in response to molar increments of plasma glucose concentration during the graded glucose.
(Modified from Conlin PR, et al

(Modified from Conlin PR, et al
Fig. 3. Plasma profiles of active GIP (A) and total GIP (B) concentrations after administration of single oral doses of sitagliptin 25 (white circles)

Fig. 3. Plasma profiles of active GIP (A) and total GIP (B) concentrations after administration of single oral doses of sitagliptin 25 (white circles)
Figure 1. Correlations between TNFα and HOMA IR in men (•) and women (○). Circulating Tumor Necrosis Factor-α Concentrations in a Native Canadian Population.

Figure 1. Correlations between TNFα and HOMA IR in men (•) and women (○). Circulating Tumor Necrosis Factor-α Concentrations in a Native Canadian Population.
Expert Panelists. Emerging CV Outcomes Trial Results: What Do They Mean for T2D Management?

Expert Panelists. Emerging CV Outcomes Trial Results: What Do They Mean for T2D Management?
EFFICACY AND MECHANISM

EFFICACY AND MECHANISM
Nat. Rev. Nephrol. doi: /nrneph

Nat. Rev. Nephrol. doi: /nrneph
Choosing glucose-lowering medication in those with established ASCVD, HF, and CKD. CV, cardiovascular; DPP-4i, dipeptidyl peptidase 4 inhibitor; GLP-1.

Choosing glucose-lowering medication in those with established ASCVD, HF, and CKD. CV, cardiovascular; DPP-4i, dipeptidyl peptidase 4 inhibitor; GLP-1.
Nat. Rev. Endocrinol. doi: /nrendo

Nat. Rev. Endocrinol. doi: /nrendo
Nat. Rev. Clin. Oncol. doi: /nrclinonc

Nat. Rev. Clin. Oncol. doi: /nrclinonc
Antihyperglycemic therapy in type 2 diabetes: general recommendations.

Antihyperglycemic therapy in type 2 diabetes: general recommendations.

Similar presentations

Ads by Google